Ravi Patel, MD
Retina Specialist · Toms River, NJNPI 1013280890
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 44.6% of the total. Reporting peaked in 2023 at $8,111 and has fallen 90.3% since, to $786 in 2025.
Across 69 payments — averaging $263.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$8K
- Bausch & Lomb Americas Inc.$5K
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$1K
- Alcon$520
- Samsara Vision$433
- plus $738 from 9 others
What the payments were for
- Consulting fees$7,88543%
- Speaking & faculty fees$6,89738%
- Travel & lodging$8104%
- Food & beverage$2,56114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 10 | $8,105 |
| Bausch & Lomb Americas Inc. | 3 | $5,001 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $2,157 |
| AbbVie | 1 | $1,200 |
| Alcon | 18 | $520 |
| Samsara Vision | 2 | $433 |
| Novartis | 5 | $207 |
| Cardinal Health 110 LLC | 1 | $150 |
| Regeneron Healthcare Solutions, Inc. | 3 | $148 |
| Oyster Point Pharma, Inc. | 4 | $88 |
| Harrow Eye, LLC | 2 | $44 |
| Sun Pharmaceutical Industries Inc. | 3 | $42 |
| EMD Serono, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $17 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$8,607
- ENVISTA ENVY$4,900
- DURYSTA$1,200
- XEN GLAUCOMA TREATMENT SYSTEM$1,200
- Tecnis IOL$640
- Implantable Miniature Telescope$416
- CATALYS SYSTEM$252
- BEOVU$124
- Centurion$122
- EYLEA$100
How this compares
$18,153 in reported general payments places this provider in the 75th percentile of 35 retina specialist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 17 | $2,131 |
| Brimonidine Tartrate | 11 | $830 |
| Prednisolone Acetate | 16 | $568 |
| Latanoprost | 46 | $295 |
| Ketorolac Tromethamine | 24 | $246 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Toms River
- Haris AminToms River$1K
- Mohammedyusuf HajeeToms River$1K
- Ahsan HussainToms River$488
- Howard FineNew Brunswick$955K
- Joshua MaliFlemington$230K
- Jonathan PrennerNew Brunswick$215K
- Leonard FeinerUnion$72K
- Daniel RothNew Brunswick$61K
- Sumit ShahNew Brunswick$41K
- Vatsal DoshiMillburn$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.